[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:hepatocellular-malignant-neoplasm-not-otherwise-specified":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":28,"states":29},"Hepatocellular Malignant Neoplasm, Not Otherwise Specified",3,[7,15,22],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT04634357","ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma",[11],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:17:21.315591Z","2026-07-19T19:36:05.119597Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT04134559","Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma",[19],"Phase 2","2026-08-26T02:16:42.787115Z","2026-05-05T02:43:27.799178Z",{"nct_id":23,"title":24,"phases":25,"status":12,"updated_at":26,"content_modified":27},"NCT05556642","Relapsed and Refractory Hepatoblastoma: A Prospective Registry and Liver Tumor Research Consortium Initiative",[],"2026-08-26T02:15:28.524219Z","2026-05-13T02:55:06.362594Z",[],[]]